Last reviewed · How we verify

Labtec GmbH — Portfolio Competitive Intelligence Brief

Labtec GmbH pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Sustained Release Morphine Sulfate Sustained Release Morphine Sulfate marketed Opioid analgesic Mu-opioid receptor (μ-OR) Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams University · 1 shared drug class
  2. Ajay Wasan, MD, Msc · 1 shared drug class
  3. Alza Corporation, DE, USA · 1 shared drug class
  4. Archimedes Development Ltd · 1 shared drug class
  5. Asbjørn Mohr Drewes · 1 shared drug class
  6. BioDelivery Sciences International · 1 shared drug class
  7. Boston Children's Hospital · 1 shared drug class
  8. AdventHealth · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Labtec GmbH:

Cite this brief

Drug Landscape (2026). Labtec GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/labtec-gmbh. Accessed 2026-05-14.

Related